Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: C Wright who wrote (7359)	4/22/1998 9:08:00 AM
From: C Wright	Read Replies (2) \| Respond to of 9262

[ALMI] Nice relationship with MARG and PQT ... biz.yahoo.com Bid already 1+ at 3-3/16 ... Happy Trades !! CW

To: C Wright who wrote (7359)	4/26/1998 1:26:00 AM
From: scaram(o)uche	Respond to of 9262

[ chat, Carol ] They changed their name recently and relocated the company to accomodate a new CEO. Prosorba has been around forever. CEO is the guy who took CYTL down the drain. I don't think that too many immunologists take the extra-corporeal concept too seriously, and there are some really serious shots at effective (and more convenient) therapy coming in the next couple of years. Sure has been a load of hype of late, however. Biotech old-timers won't appreciate that which centers on the CEO, as he bailed from his shares early at CYTL and then, IMO and in the opinion of many others, failed miserably. Recommendation? Don't tread long-term. Next breath? I haven't seen the data, and I may be making one hell of a fool of myself. Doubt it, but have you got a pointer to a release where any data is discussed? Rick